New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
海角七号
发表于 2024-1-2 20:27:48
347
0
0
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients. At this point, 12 indications for tirizizumab have been approved in China.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- BeiGene: NASDAQ stock code will be changed to 'ONC'
- BeiGene NASDAQ stock code will be changed to 'ONC'
- BeiGene issues 100000 shares, with an increase of 0.007%
- BeiGene and BeiZeAn are approved for new indications in the United States
- Sanofi's BTK inhibitor is declared for market in China
